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We analyzed patient data from the mul-
ticenter phase III colon adenoma preven-
tion trial (ClinicalTrials.gov identifiers 
NCT00005882, NCT00118365) (7). 
Three hundred seventy-five patients were 
enrolled, and the study was halted by the 
Data Safety Monitoring Board after 267 
patients completed end-of-study colonos-
copies (because of the study meeting its 
efficacy endpoints). The Data Safety 
Monitoring Board monitored all safety and 
efficacy endpoints. Blood specimens were 
collected from 228 consenting study 
patients for genotyping analysis after 
November 2002 (including 159 of the 246 
patients randomly assigned before this 
date, and 69 of the 129 patients randomly 
assigned after this date) when the protocol 
was modified in light of data demonstrating 
the importance of the ODC1 single-nucleo-
tide polymorphism (3). ODC1 (rs2302615) 
genotyping was conducted on patient-
derived genomic DNA using allele-specific 
TaqMan probes as described previously 
(1). Rectal tissue polyamine content was 
determined as described previously (10,11) 
using three of the eight randomly selected 
rectal mucosal biopsy specimens. Tissue 
polyamine response was performed for 
response values ranging from 25% to 45%.
The ODC1 genotype was analyzed 
under a dominant model: AA/GA vs GG 
patients. Wilcoxon rank sums tests were 
performed on non-normally distributed 
continuous variables across two genotype 
groups. The x2 or Fisher exact test was used 
to assess the association between baseline 
categorical variables and genotype group. 
Log binomial regression was performed on 
the primary outcome (adenoma recur-
rence), with the variables treatment group, 
age, sex, race (white vs other), aspirin use, 
ODC1 genotype (in the dominant model), 
and a term representing the treatment by 
genotype interaction. For secondary out-
comes (rectal tissue polyamine response, 
cardiovascular toxicity, ototoxicity), the ef-
fects of treatment group, genotype, and 
interaction between treatment and geno-
type were examined using full log binomial 
models. For the analysis of the secondary 
outcome gastrointestinal toxicity, because 
of imbalances in the distribution by gender 
and race, the effects of treatment group, 
A single-nucleotide polymorphism in 
intron 1 of human ornithine decarboxylase-1 
(ODC1) has functional consequences for 
binding by E-box activators and repres-
sors (1,2) and has been investigated as a 
marker for colorectal adenoma risk (3–5). 
The reported minor A allele frequency 
is approximately 25%, and despite differ-
ences across race or ethnicity, ODC1 ge-
notype distribution is in Hardy–Weinberg 
equilibrium within each race (white, black, 
Hispanic, Asian) (2,6). Individuals homo-
zygous for the ODC1 minor A allele have 
reduced risk of adenoma recurrence com-
pared with those with the major G allele 
(3,5). Furthermore, the ODC1 A allele 
(AA or GA genotype but not GG geno-
type) and reported aspirin use have been 
associated with reduced colon polyp 
recurrence (3–5) and with a statistically 
significant 50% reduced risk of advanced 
adenomas (4). Recently, we demonstrated 
the efficacy of a polyamine inhibitory 
combination of long-term daily oral 
d,l-a-difluoromethylornithine and sulindac 
among colorectal adenoma patients (7); 
however, treatment was associated with 
modest subclinical ototoxicity (8) and a 
greater number of cardiovascular events 
among patients with high baseline car-
diovascular risk (9). Here, we investigate 
whether the ODC1 genotype differen-
tially affects adenoma recurrence, tissue 
polyamine responses, or toxicity profiles 
after eflornithine and sulindac treatment 
compared with placebo.
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The ornithine decarboxylase-1 (ODC1) polymorphism at position +316 affects binding 
by transcriptional activators and repressors and modulates the risk of metachro-
nous colorectal adenomas, particularly in association with aspirin use. We investi-
gated the effects of ODC1 after treatment with difluoromethylornithine (eflornithine)/
sulindac or placebo. Two hundred twenty-eight colorectal adenoma patients in a 
randomized phase III trial were genotyped for ODC1. We used Wilcoxon rank sums 
tests on non-normally distributed continuous variables across two genotype groups, 
x2 or Fisher exact test to assess the association between baseline categorical variables 
and genotype group, and log binomial regression for the primary (adenoma recur-
rence) and secondary outcomes (tissue polyamine response, cardiovascular toxicity, 
gastrointestinal toxicity, and ototoxicity). All statistical tests were two-sided. In 
binomial regression models with variables age, sex, race, aspirin use, treatment, and 
ODC1 genotype, treatment was the only statistically significant factor associated 
with differences in adenoma recurrence or tissue polyamine response. A statistically 
significant interaction was detected between ODC1 genotype and treatment with 
respect to adenoma recurrence (placebo group: GG, 50%, AA/GA: 34%; treatment 
group: GG, 11%, AA/GA, 21%; P
interaction
 = .038). Excess ototoxicity was observed 
among ODC1 AA patients receiving treatment, but the interaction of genotype and 
treatment on ototoxicity was not statistically significant (P = .45).
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treatment after adjustment in the full re-
gression model was 0.39 (95% confidence 
interval = 0.24 to 0.66). A statistically sig-
nificant interaction was detected between 
ODC1 genotype and treatment in this 
model with respect to adenoma recurrence 
(placebo group: GG, 50%, AA/GA: 34%; 
treatment group: GG, 11%, AA/GA, 21%; 
Pinteraction = .038; Table 2). There were no 
statistically significant associations between 
treatment and ODC1 genotype group with 
regard to cardiovascular or gastrointestinal 
adverse events (Table 2). No associations 
of treatment with ototoxicity were observed 
for ODC1 genotype using the dominant 
Table 1. Clinical characteristics of all subjects at baseline by ODC1 genotype*
Characteristics
ODC1 AA/GA 
genotype (n = 102)
ODC1 GG 
genotype (n = 126) P†
Mean age ± SD, y 60.2 ± 8.4 62.6 ± 8.7 .024‡
Sex, No. (%)
Male 77 (75) 96 (76) .90
 Female 25 (25) 30 (24)
Race, No. (%)
White 84 (82) 107 (85) .007§
Black 3 (3) 4 (3)
Hispanic 4 (4) 12 (10)
Asian 9 (9) 1 (1)
Other 2 (2) 2 (2)
Treatment group, No. (%)
Eflornithine + sulindac 46 (45) 71 (56) .09
 Placebo 56 (55) 55 (44)
Low-dose aspirin use, No. (%)
Yes 44 (43) 54 (43) .97
No 58 (57) 72 (57)
Median No. (minimum–maximum) 2.00 (1–11) 2.00 (1–16) .41‡
Location of largest prior polyp, No. (%)
Rectum 26 (25) 23 (18) .19
 Colon 76 (75) 103 (82)
Prior polyp histology, No. (%)
Tubular 76 (75) 99 (79) .03‡
Adenoma-NOS 6 (6) 8 (6)
Tubulovillous 10 (10) 17 (13)
Villous 7 (7) 1 (1)
Carcinoma in-situ 3 (3) 0 (0)
Tubular adenoma, high-grade dysplasia 0 (0) 1 (1)
Largest polyp ≥1 cm, No. (%) 25 (25) 40 (32) .23
Treatment for prior polyp, No. (%)
Complete endoscopic removal 92 (90) 117 (93) .47
 Surgery 10 (10) 9 (7)
Baseline tissue polyamine content,║ 
median (range), nmol/mg protein
Putrescine 0.47 (0.01–4.60) 0.56 (0.01–5.29) .48‡
Spermidine 1.99 (0.76–9.18) 2.17 (1.05–8.97) .08‡
Spermine 6.82 (2.29–19.86) 7.29 (2.72–22.85) .23‡
Spermidine to spermine ratio 0.30 (0.19–0.98) 0.31 (0.19–0.76) .23‡
* N = 228; NOS = not otherwise specified.
† P value for the x2 test is listed unless noted otherwise. All statistical tests were two-sided.
‡ P value for the Wilcoxon rank sums test.
§ P value for the Fisher exact test.
║ Tissue polyamine data missing for 1 subject with ODC1 GG genotype and 1 subject with ODC1 AA/GA 
genotype.
genotype, and interaction between treat-
ment and genotype were examined using 
log binomial models as above but lacking 
gender and race in the model. Statistical 
analyses were conducted using SAS 9.2 
statistical software (SAS, Inc, Cary, NC). 
All statistical tests were two-sided. Patients 
signed informed consent for trial inclusion 
and specimen retrieval and analysis. The 
CONTEXTS AND CAVEATS
Prior knowledge
Individuals  homozygous  for  the  minor  A 
allele  of  the  ornithine  decarboxylase-1 
(ODC1) gene have reduced risk of colorectal 
adenoma recurrence compared with  those 
with the major G allele.
Study design
The  associations  among  ODC1  genotype, 
tissue  polyamine  responses,  and  toxicity 
after  eflornithine  and  sulindac  treatment 
compared with  placebo were  investigated 
with patient data from a multicenter phase 
III  clinical  trial  of  colorectal  adenoma 
prevention.
Contribution
A  statistically  significant  interaction 
between  ODC1  genotype  and  treatment 
with  respect  to  adenoma  recurrence  was 
found.  Individuals  homozygous  for  the  G 
allele had lower risk of adenoma recurrence 
after  eflornithine  and  sulindac  treatment 
than  those  homozygous  or  heterozygous 
for the A allele. ODC1 AA patients receiving 
treatment  had  excess  ototoxcity,  but  the 
interaction  between  genotype  and  treat-
ment  on  ototoxicity  was  not  statistically 
significant.
Implications
Although  the minor A  allele  protects  indi-
viduals  against  colorectal  adenoma  recur-
rence, especially in association with aspirin 
use,  carrying  two  copies  of  the  G  allele 
reduces  the  risk  of  recurrence  after  treat-
ment with eflornithine and sulindac.
Limitations
Study  limitations  include  small  sample 
size and a lack of balance in baseline char-
acteristics across ODC1 genotype groups. 
Sulindac  and  its  metabolites  also  have 
polyamine inhibitory properties and other 
antineoplastic  mechanisms,  such  as 
cyclooxygenase  inhibition  and  b-catenin 
degradation, which could account  for  the 
findings.
From the Editors
study was approved by the University of 
California Irvine Institutional Review 
Board and by each institutional review 
board at participating study sites.
ODC1 genotype distribution was 126 
GG (55%), 87 GA (38%), and 15 AA (7%). 
Patients in the two genotype groups dif-
fered in several baseline clinical character-
istics (age, race, prior polyp histology; 
Table 1). ODC1 genotype was not statisti-
cally significantly associated with a tissue 
putrescine response or spermidine to 
spermine ratio response in the full regres-
sion models (data not shown). The relative 
risk for adenoma recurrence related to 
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model (P = .26; Table 2). Under a log-
additive model, ODC1 genotype was signif-
icantly associated with increased ototoxicity 
in the treatment arm (P = .015). Among 
patients receiving placebo or treatment, 
ototoxicity occurred in 23% vs 22% of 
ODC1 GG patients, 20% vs 21% of ODC1 
GA patients, and 0% (zero of seven) vs 
57% (four of seven) of ODC1 AA patients, 
respectively. However, a test for inter-
action of genotype and treatment on 
ototoxicity was not statistically significant 
(P = .45).
Here, we observed that the adenoma 
inhibitory effect of eflornithine and sulin-
dac was greater among those with the 
major G homozygous ODC1 genotype, in 
contrast to previous reports showing 
decreased risk of recurrent adenoma among 
colorectal adenoma patients receiving aspi-
rin and carrying at least one A allele (3–5). 
ODC1 genotype distribution was similar to 
that reported in previous aspirin-based 
trials (3–5), and the A allele was associated 
with a non-statistically significant lower 
recurrent adenoma risk in the placebo 
group, consistent with previous reports 
(3,5). It is possible that the previously 
observed interaction with the ODC1 A al-
lele and aspirin may reflect a mechanism 
unique to aspirin or that alternate mecha-
nisms are involved when nonsteroidal anti- 
inflammatory drugs are combined with an 
ODC inhibitor.
Study limitations include small sample 
size and a resultant limited number of 
events, as well as the lack of balance in 
baseline characteristics across ODC1 geno-
type groups. It is acknowledged that sulin-
dac and its metabolites have polyamine 
inhibitory properties (12) as well as other 
antineoplastic mechanisms, such as cyclo-
oxygenase inhibition (13) and b-catenin 
degradation (14), which were not accounted 
for and could underlie our findings.
These results demonstrate that ODC1 A 
allele carriers differ in response to pro-
longed exposure with eflornithine and 
sulindac compared with GG genotype 
patients. ODC1 A allele carriers experience 
less treatment-related benefit (ie, meta-
chronous adenoma risk reduction) and 
potential for higher risk of developing oto-
toxicity, especially among the AA homozy-
gotes. Whether the A allele is a risk or 
protective allele may, therefore, depend on 
the tissue context or extent of polyamine 
inhibition. A major impediment to the 
translation of cancer chemoprevention re-
search into clinical practice has been mar-
ginal agent efficacy and toxicities that 
exceed benefit (15,16). In this study, we 
identify genetic features that may be 
markers for both treatment benefit and 
toxicity. These results encourage evalua-
tion in future polyamine inhibitory che-
moprevention trials, as planned in the 
cooperative group setting (17).
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